All In Biotech

Free tool

FAERS Monitor: Fanapt

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022192 or its brand name (Fanapt, Iloperidone). Reports on generic versions are filed under their own applications.

Reports

1,476

Serious

722

49% of reports

Hospitalization

222

Death reported

60

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective108
  • dizziness107
  • insomnia83
  • weight increased83
  • anxiety70
  • fatigue68
  • nausea54
  • dyskinesia51
  • suicidal ideation49
  • dyspnoea48
  • off label use48
  • somnolence48
  • aggression45
  • tachycardia43
  • vomiting43

Reports by year received

View as table
YearReports
20091
201075
2011134
2012393
201376
201484
201564
201660
201782
201876
201987
202046
202149
202234
202327
202428
202573
202687

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,683 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dyskinesiaSignal5117.913.7798
aggressionSignal4512.89.6480
suicidal ideationSignal497.65.8277
tachycardiaSignal436.95.1212
weight increasedSignal835.34.3287
insomniaSignal834.43.6221
anxietySignal703.52.8125
somnolenceSignal483.42.680
dizzinessSignal1073.12.5150
vomiting431.31.03
fatigue681.21.03
dyspnoea481.20.92
drug ineffective1081.21.03
nausea541.00.70
off label use480.80.63

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.